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Summary
Epidermal Langerhans cells (LCs), a distinct skin-
resident dendritic cell population, acquire antigen
in the skin and migrate to draining lymph nodes
where they are thought to initiate adaptive immune re-
sponses. To examine the functional requirement of
LCs in skin immunity, we generated BAC transgenic
mice in which the regulatory elements from human
Langerin were used to drive expression of diphtheria
toxin. The resulting mice have a constitutive and dura-
ble absence of epidermal LCs but are otherwise intact.
Unexpectedly, we found that contact hypersensitivity
(CHS) was amplified rather than abrogated in the ab-
senceofLCs.Moreover,weshowed thatLCsactduring
the priming and not the effector phase. Thus, LCs not
only were dispensable for CHS, but they served to
regulate the response, a previously unappreciated
function.
Introduction
Dendritic cells (DCs) are very efficient at activating naive
T cells in vitro and in vivo (Banchereau et al., 2000). They
can acquire antigen via multiple routes including endo-
cytosis, pinocytosis, and direct infection by pathogens
(Banchereau et al., 2000). DCs also have an array of
receptors for pathogen-associated molecular patterns
that stimulate DC activation and maturation (Iwasaki
and Medzhitov, 2004). Though DCs as a class share
these properties, they are nevertheless functionally
and phenotypically diverse. They have been categorized
based on the expression of numerous markers including
CD8a, CD4, CD11b, B220, and C-type lectin receptors
such as DEC205 (Henri et al., 2001; Shortman and Liu,
2002). Although DCs were initially identified because of
their stimulatory capacity, a growing body of data has
demonstrated that immature DCs as well as certain sub-
sets of mature DCs promote tolerance rather than immu-
nity (Mowat, 2003; Steinman et al., 2003; Steinman and
Nussenzweig, 2002).
DCs can also be categorized by whether they are res-
ident in secondary lymphoid tissue or in parenchymal
*Correspondence: dan.kaplan@yale.edutissues. Unlike DCs in secondary lymphoid tissue, tis-
sue-resident DCs do not typically have direct access
to naive T cells. Rather, it is thought that these cells
function as sentinels that acquire Ag in the periphery
and become activated locally (Hemmi et al., 2001).
Once activated, they migrate to T cell zones of regional
lymph nodes (LNs), where they are thought to either
present tissue-acquired Ag or transfer Ag to resident
secondary lymphoid tissue DCs for presentation,
thereby stimulating a primary response (Carbone et al.,
2004; Romani et al., 2003). Despite evidence for priming
of some immune responses both directly by secondary
lymphoid tissue-resident DCs and in other cases by
tissue-resident DCs after migration, their relative roles
remain unclear.
Langerhans cells (LC) are a subset of tissue DCs lo-
cated in the epidermis and are thus the first APCs to
contact pathogens at the skin surface (Romani et al.,
2003). Immature LCs residing in skin collect antigen,
and upon various stimuli, they mature and migrate to
draining LNs (Hemmi et al., 2001; Kripke et al., 1990).
Thus, they are presumed to play a key role in promoting
immune responses.
LC function has been examined in a number of differ-
ent systems. Contact hypersensitivity (CHS) to cutane-
ously applied hapten, a model for contact dermatitis,
is a classical skin response in which LCs are thought
to play a role (Silberberg-Sinakin and Thorbecke, 1980).
Treatment with ultraviolet light prior to priming with
hapten eliminates LCs from the skin and inhibits the
development of CHS, thereby suggesting that LCs are
required for the development of a CHS response
(Schwarz, 1999; Toews et al., 1980). Supporting this no-
tion, more recent data have demonstrated that LCs that
have emigrated to the draining LN can directly present
antigen secreted from keratinocytes (Mayerova et al.,
2004). Moreover, LCs are sufficient for the development
of cutaneous GVHD (Merad et al., 2004). Although these
studies indicate that LCs can promote and are possibly
necessary for T cell priming, opposite conclusions have
been reached in other settings. After HSV infection of
either vaginal epithelium or abraded flank skin, the
DCs presenting HSV antigens to T cells in draining LNs
did not appear to include LCs (Allan et al., 2003; Zhao
et al., 2003). Thus, it appears that under certain circum-
stances, LCs may be dispensable for stimulation.
As this manuscript was being prepared, two groups
reported that they had developed mice that express the
diphtheria toxin (DT) receptor on LCs and have a tran-
sient depletion of LCs after injection of DT (Bennett
et al., 2005; Kissenpfennig et al., 2005). Interestingly,
one group observed that CHS was diminished, while
the other found it was unchanged in transiently LC-
depleted mice.
From these studies alone, it is clear that in spite of the
likely importance of LCs in skin immune responses, their
roles require more precise definition. We have ad-
dressed this by generating transgenic mice that contain
an attenuated form of diphtheria toxin under control of
genetic elements that restrict expression to LCs. These
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cial chromosome (BAC) containing the human Langerin
gene that is specifically expressed in LCs (Giraldo and
Montoliu, 2001; Valladeau et al., 2000). We selected a
human BAC to allow us to test for expression of the
transgene with human-specific antibodies. Once we
ascertained that the human gene expressed in mice as
predicted, we introduced diphtheria toxin sequence into
the Langerin gene contained in the BAC and made an-
other round of transgenic mice. Some of these founder
lines constitutively lacked epidermal LCs, while other
DC subsets remained intact. These mice allowed us to
experimentally test the role of LCs in a prototypical CHS
response. Unexpectedly, we found that CHS was am-
plified in the absence of LCs. Thus, LCs not only were
dispensable for CHS, but they served to regulate the
response.
Results
Generation of Human Langerin Transgenic Mice
To generate a mouse with a selective absence of LCs,
we expressed diphtheria toxin in LCs by a genomic
BAC transgenic system (Giraldo and Montoliu, 2001).
We chose to use human-derived BACs to facilitate dis-
crimination of the transgene from the orthologous engo-
denous mouse gene through the use human-specific
reagents. This strategy has been successful in other
cases; human genes on BACs are frequently (but not al-
ways) expressed in a tissue-specific manner (Attie et al.,
2001; Feng et al., 2001; Miano et al., 2002).
To target LCs, we used BAC RP11-504o1, which con-
tains the human gene for Langerin (huLangerin), which is
selectively expressed by LCs (Valladeau et al., 2000). A
71 kb NotI fragment of RP11-504o1 containing Langerin
and 26 kb of upstream sequence was used to generate
transgenic mice. Founders were screened by PCR with
primers specific for each end of the NotI fragment to en-
sure incorporation of the full-length DNA. A total of 8
founders from 66 live births were generated.
Transgenic huLangerin Is Expressed
in Epidermal LCs
To validate LC-specific expression of the huLangerin
transgene, we prepared epidermal sheets from ear and
flank skin from four independent transgenic lines. Since
LCs are the only epidermal cells that constitutively ex-
press MHC-II (Tsuruta et al., 1999), sheets stained with
MHC-II and anti-huLangerin were examined by immuno-
fluorescence (Figure 1A). Three out of four founder lines
demonstrated strong expression of human Langerin in
all LCs in every field examined. In one founder, approx-
imately 50% of the LCs expressed detectable levels of
huLangerin; this founder was not analyzed further. Cells
expressing MHC-II also costained for CD11c (data not
shown). There was no detectable huLangerin expres-
sion by MHC-II-negative cells.
To quantify the number of LCs expressing huLangerin,
we examined epidermal single-cell suspensions by flow
cytometry. As was seen by immunofluorescence, virtu-
ally all of the MHC-II+ cells expressed huLangerin
(Figure 1B, left). These MHC-II+/huLangerin+ cells also
expressed murine Langerin, thereby firmly establishing
them as LCs (Figure 1B, middle and right). We also ex-amined dermal single-cell suspensions and found that
transgenic huLangerin was expressed in a small subset
of CD11c+ cells (Figure 1C, left). The majority of these
cells also expressed murine Langerin (Figure 1C, middle
and right). Therefore, these are likely either LC precur-
sors that reside in the dermis or epidermal LCs in the
process of migrating though the dermis to regional
LNs. The small number of dermal cells expressing
murine but not human Langerin may reflect a delay in
expression of the transgene compared with the engode-
nous murine locus. Thus, the NotI fragment of RP11-
504o1 that contains the human gene for Langerin accu-
rately expressed in all murine epidermal LCs and was
a good candidate to drive expression of diphtheria toxin.
Generation of Langerin-DTA Mice
We modified RP11-504o1 to drive the expression of
diphtheria toxin in LCs by using homologous recombi-
nation in E. coli as described by Yang et al. and modified
by Misulovin et al. (Misulovin et al., 2001; Yang et al.,
1997). We inserted an internal ribosome entry sequence
(IRES), which allows for translation of polycistronic
mRNA followed by an attenuated form of diphtheria
toxin subunit A (DTA) (Maxwell et al., 1986) into the 30
untranslated region (UTR) of the huLangerin gene (Fig-
ure 2A). Successfully recombined BAC clones were
screened by PCR (data not shown) and confirmed by re-
striction digest with Hyp99I, which is introduced with the
DTA cDNA (Figure 2B). Insertion of the IRES-DTA con-
struct into RP11-504o1 was verified by the absence of
a 71 kb band, which is seen in the unmodified DNA
(left lane) and the appearance of two novel 40 kb and
31 kb bands seen in two independent clones (two right
lanes). A 72 kb NotI fragment of the modified BAC was
used to inject pronuclei from pure FVB embryos in order
to generate a new set of transgenic mice. A total of 7 full-
length founders from 28 live births were generated. All
founders appeared healthy and grossly normal.
Transgenic Langerin-DTA Mice Lack Epidermal LCs
Transgenic founders were screened by immunofluores-
cence for the absence of LCs by staining for MHC-II in
whole mounted epidermal sheets. Five of the founders
showed no decrease of epidermal LCs and were not ex-
amined further. Two transgenic founders, however,
showed a complete absence of MHC-II-positive cells
in all fields examined (Figure 3A). Similarly, staining for
MHC-II in transverse ear sections revealed an absence
of epidermal LCs in transgenic mice. Importantly, MHC-
II-positive APCs in the dermis were still present in
Langerin-DTA mice (Figure 3B). We also did not see a
reduction of gd+ (Vg5+) dendritic epidermal T cells (see
Figure S1 in the Supplemental Data available with this
article online) or the total number of epidermal gd T cells.
Flow cytometry of single-cell epidermal suspensions
from Langerin-DTA mice revealed a virtually complete
absence (30-fold reduction) of LCs in the epidermis (Fig-
ures 4A and 4D, p < 0.0001). In contrast, there was no
significant reduction of MHC-II- or CD11c-positive cells
in dermal suspensions from Langerin-DTA mice com-
pared with littermate controls (Figures 4B–4D, p = 0.62).
Dermal dendritic cells and macrophages are the primary
MHC-II-positive cells present in noninflamed dermis.
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pressed by All Epidermal LCs
(A) Epidermal sheets from transgene positive
(top, Tg+) and littermate controls (bottom,
Tg2) were stained for MHC-II to identify LCs
(green, left) and for transgenic huLangerin
(red, middle). Cells expressing both markers
appear yellow when overlayed (right). Data
are representative of all fields examined in
three independent founders.
(B) FACS analysis of single-cell epidermal
suspensions gated on live MHC-II-positive
cells. Levels of huLangerin (left, Tg+ thick
line, Tg2 thin line, isotype control shaded)
and comparison of huLangerin and muLan-
gerin from Tg2 (middle) and Tg+ (right). Num-
bers in quadrants indicate percentage of total
cells.
(C) Analysis of dermal cells as in (B).Thus, as expected, we did not detect any dermal B220+/
MHC-II+ B cells (Figure 4C).
Flow cytometry of LN and spleen demonstrated that
DC subsets were equivalent in both Langerin-DTA and
control mice (Figure S2). Moreover, we also found equiv-
alent numbers of resident murine Langerin+/CD11c+
cells in secondary lymphoid tissues and thymus from
wild-type and Langerin-DTA mice (Figures 5A–5D), indi-
cating that the deficit in these mice is restricted to epi-
dermal LCs. The presence of murine Langerin+ cells in
mesenteric lymph node, thymus, and spleen has been
previously reported (McLellan et al., 2002; Valladeau
et al., 2002). Given the location of these cells in tissues
that do not receive lymph from the skin as well as the
fact that they are retained in Langerin-DTA transgenic
mice that nonetheless are devoid of epidermal LCs, it is
unlikely that they represent mature epidermal LCs that
have migrated from skin. To directly examine the pres-
ence in cutaneous lymph node of migrating epidermal
LCs, we painted FITC on the skin of both wild-type and
Langerin-DTA mice. It is evident that among CD11c+
LN cells 4 days after painting, the migrating (FITC+) der-
mal DCs that are DEC-205dim are intact, whereas the
migrating DEC-205bright cells, which are thought to be
derived from epidermal LCs, are absent (Figure 5E;Kamath et al., 2002). Taken together, these data first of
all reinforce the notion that migrating LCs are DEC-
205bright, as this population is missing in FITC-painted
Langerin-DTA mice. They also indicate that most resi-
dent Langerin+ cells in cutaneous LN must not be derived
from migrating LCs. Though all LCs express Langerin,
not all Langerin-expressing cells are derived from epi-
dermal LCs. This is an important point, as this substantial
Langerin+ population was depleted in systems that elim-
inate LCs though the administration of DT in mice that ex-
press the diphtheria toxin receptor under control of the
native langerin locus (Bennett et al., 2005; Kissenpfennig
et al., 2005). In contrast, Langerin-DTA mice have a com-
plete absence of epidermal LCs yet retain other immuno-
logically important cell types that normally reside in the
skin and secondary lymphoid tissue.
Langerin-DTA Mice Have Enhanced
Contact Sensitivity
Contact hypersensitivity (CHS) to epicutaneously ap-
plied hapten is the classic assay for examining cutane-
ous adaptive immunity. Importantly, CHS priming does
not require prior disruption of the epidermis or stratum
corneum, thus mimicking as closely as possible the
manner in which the skin is normally exposed to
Immunity
614Figure 2. Generation of Langerin-DTA Mice
(A) Schematic representation of the shuttle
vector used to introduce IRES-DTA into RP11-
504o1 (top line). The vector contains an
IRES-DTA cassette flanked by two 1.0 kb
sequences homologous to the 30 end of the
Langerin gene (exon VI and 30UTR) in RP11-
504o1 (middle line). The final recombined
product is pictured on the bottom line.
Hyp99I sites are indicated as ‘‘H.’’
(B) DNA digested with Hyp99I from either the unmodified BAC (wt) or two independent recombined clones (1 and 2) run on a 1% agarose pulse
field gel. Note that a 71 kb band present in the wild-type is replaced by 40 kb and 31 kb bands, indicating the successful insertion of the IRES-DTA
cassette.environmental antigens. CHS to two commonly used
haptens, DNFB (2,4-dinitro-1-fluorobenzene) and oxaz-
alone, are mediated by both CD4 and CD8 in a Th1/
Tc1 response (Gocinski and Tigelaar, 1990; Wang et al.,
2000). Having established that Langerin-DTA mice lack
epidermal LCs, we addressed their role in the develop-
ment of CHS. In the priming phase, hapten is painted
on shaved but otherwise intact skin. Five days later,
mice are rechallenged with the hapten on the ear and
the strength of the hapten-specific response is mea-
sured by the degree of ear swelling after 24 hr.
The classical models of LC function in CHS would pre-
dict that Langerin-DTA mice would have an absent or
greatly diminished CHS response (Bennett et al., 2005;
Kissenpfennig et al., 2005; Silberberg-Sinakin and Thor-
becke, 1980). However, we were surprised to find that
ear swelling was consistently approximately 2-fold
greater in Langerin-DTA mice than in age- and sex-
matched littermate controls (Figure 6A). This enhanced
response was seen in both founder lines (data not
shown). Swelling persisted and was still evident 3 days
after DNFB challenge (Figure 6C). The enhanced CHS re-
sponses were not unique to DNFB, since it was also
seen with oxazalone (Figure 6B). Moreover, this effectwas not due to nonspecific enhancement of inflamma-
tion since both Langerin-DTA and control mice devel-
oped a similar degree of ear swelling after application
of the irritant contactants sodium dodecyl sulfate
(SDS) or benzalkonium chloride (Figures 6D and 6E). Al-
though we saw an enhanced immune response to epi-
cutaneously applied antigen, T cells from Langerin-
DTA and control animals demonstrated a similar degree
of in vitro proliferation to OVA peptide when harvested
7 days after footpad immunization with OVA in CFA
(data not shown).
Enhanced CHS due to Increased T Cell Priming
The mechanism responsible for the enhanced CHS re-
sponse could have been operative during the priming
phase, effector phase, or both. To distinguish among
these possibilities, we employed a series of adoptive
transfer experiments. Although, as expected in such
transfer systems, the overall amount of ear swelling
was less than was observed in intact mice (Wang
et al., 2000), we noted an almost 2-fold increase in ear
swelling in wild-type animals that received primed
LN cells from Langerin DTA-mice compared with
cells from littermate controls (Figure 7A). AdoptivelyFigure 3. Langerin-DTA Mice Lack Epidermal LCs
(A) Epidermal sheets from littermate control (Tg2, top) and Langerin-DTA (Tg+, lower panels) mice were stained with MHC-II (green, left) to iden-
tify LCs and with DAPI (blue, right) to identify cell nuclei regardless of MHC-II expression. Data are representative of all fields examined.
(B) Transverse sections of frozen skin stained for MHC-II from littermate control (Tg2, top) or Langerin DTA (Tg+, bottom). LCs are indicated by
asterisks. Right panels are a magnified view (5003 original magnification) of the epidermis from the same sections seen on the left (1003 original
magnification). Data are representative of two independent founders.
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LCs
(A and B) FACS analysis of single-cell epider-
mal (A) or dermal (B) suspensions gated on
live cells from either Langerin-DTA (Tg+) or
littermate controls (Tg2). Cells were stained
with MHC-II to identify LCs and are plotted
against an unstained channel for clarity. Num-
bers above gates indicate percentage of
positive cells.
(C) Expression of CD11c and B220 on MHC-
II+ dermal cells. Data in (A)2(C) are represen-
tative of two independent founders.
(D) The percentage of MHC-II+ cells found in
the epidermis and dermis from both Lan-
gerin-DTA and littermate control animals are
plotted from multiple experiments to better
represent the range of data obtained. There
is a significant reduction of MHC-II cells in
epidermis (p < 0.001) but not in dermis (p =
0.62).transferred cells from Langerin-DTA and control mice
had similar numbers of B cells, CD4 T cells, and CD8 T
cells (data not shown). In the reciprocal transfer experi-
ment, Langerin-DTA and littermate controls received LN
cells from primed wild-type mice. Both groups of ani-
mals developed a similar degree of ear swelling (p =
0.42) that was significantly greater than mice injected
with PBS (Figure 7B, p < 0.05) or cells from naive mice
(data not shown). Thus, the absence of epidermal LCs
leads to enhanced CHS during the afferent phase, pre-
sumably through increased T cell priming. In contrast,
the LC-deficient environment did not promote a more
vigorous effector phase.
Discussion
In this paper, we have described an otherwise normal
mouse that constitutively lacks a single DC subtype, epi-
dermal LCs. We then used this model to demonstrate
that the lack of LCs leads to an enhanced rather than in-
hibited CHS response. Finally, we went on to show via
cell-transfer experiments that LCs act at the priming
rather than effector phase of the response. These results
alter our view of LCs by demonstrating that they are not
required for the presentation of antigens acquired in skin
but instead have a regulatory function. The findings
highlight the importance of examining individual DC
subsets in vivo and demonstrate that different DC sub-
sets play particular roles in the generation and regula-
tion of immune responses.
Although LCs are not required for CHS responses,
they appear to have a stimulatory capacity in certain
other settings. In a model of MHC-disparate allogeneic
GVHD, LCs have been shown to be sufficient for the de-
velopment of cutaneous disease (Merad et al., 2004).
Similarly, in a separate model, ovalbumin secreted from
keratinocytes appears to be presented to TCR trans-
genic T cells by LCs and not by other DC subsets
(Mayerova et al., 2004). In addition, LCs have been pre-
sumed to play a key role in CHS based on findings that
UV irradiation prior to priming with hapten leads not
only to abrogated CHS responses but also to hapten-
specific tolerance (Schwarz, 1999; Toews et al., 1980).
An explanation for the disparity between these resultsand our findings could relate to the very high frequen-
cies of antigen-specific T cells in the first two models;
under such circumstances, the potential for LCs to stim-
ulate T cells may be dominant over regulatory function.
Importantly, the potential involvement of dermal DCs
in these systems was not examined. This is particularly
relevant for studies involving UV irradiation of the skin,
since irradiation depletes both LCs and dermal DCs
and has numerous other effects on the skin and immune
system (Clydesdale et al., 2001; Duthie et al., 2000). Re-
cent work with cutaneous HSV infection suggests that
LCs are not responsible for presentation of antigens to
T cells and raises the possibility that LCs (and/or poten-
tially dermal DCs) could transport antigen to skin drain-
ing LNs and then transfer antigen to CD8+ DCs (Allan
et al., 2003; Carbone et al., 2004). Thus, although LCs
may initiate certain types of responses, in many cases
T cell activation can be accomplished in vivo by other
APCs. In CHS, presumably dermal DCs, which are known
to collect cutaneous Ags and migrate to LNs, perform
this function (Itano et al., 2003).
Very recently it was reported by Kissenpfenning et al.
and Bennett et al. that mice in which the gene for the
diphtheria toxin (DT) receptor is ‘‘knocked-in’’ to the lan-
gerin locus have a transient depletion of Langerin+ cells
after injection of DT (Bennett et al., 2005; Kissenpfennig
et al., 2005). Although both groups used a similar tech-
nique, Kissenpfenning et al. did not identify any specific
role for LCs while Bennett et al. observed a modest de-
crease in CHS. Neither of these systems discerned an
enhanced CHS responses as seen consistently in our
mice. There are many reasons why the regulatory role
of LCs could have been missed in these transient deple-
tion studies. It is possible that the regulatory effects of
LCs require their constitutive presence and short-term
depletion is not sufficient to reveal this. A key differ-
ence, however, between our transgenic and the knockin
systems could be the expression of the DT receptor on
Langerin+ cells other than LCs. DT injection eliminated
epidermal LCs as well as a substantial portion of the
Langerin+, CD11c+ CD8+ DCs in skin-draining LNs in
Kissenpfenning et al. (and presumably Bennett et al.,
though this was not as clearly documented). Langerin
is also expressed by CD8+ DCs in the spleen (McLellan
Immunity
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Cells Are Retained but Migrating DEC-205bright
LCs Are Absent in Langerin-DTA Mice
(A–D) FACS analysis of (A) cutaneous lymph
node, (B) mesenteric lymph node, (C) spleen,
and (D) thymus from Langerin-DTA (Tg+) or lit-
termate controls (Tg2). Live gated cells were
stained with CD11c and muLangerin. Numbers
in the gates indicate the percentage muLan-
gerin cells in each tissue.
(E) Cutaneous lymph nodes were harvested
4 days after mice were painted on shaved ab-
domens with 100 ml of 0.5% FITC and stained
with anti-CD11c and DEC-205. Live CD11c+
gated cells from wild-type mice (Tg2) and Lan-
gerin-DTA mice (Tg+) are shown. These data
are representative of three independent ex-
periments.et al., 2002; Valladeau et al., 2002), and many of these
cells also eliminated after DT injection (Kissenpfennig
et al., 2005). Since the CD8+ DC subset has been shown
to present antigen to T cells after cutaneous infection
(Allan et al., 2003), its reduction could decrease the CHS
response that otherwise would have been increased
in the absence of LCs. In contrast, our Langerin-DTA
mice do not have a detectable absence of Langerin+
DCs (or any other DC subset) in LN or spleen (Figures
5A–5D and Figure S2). Importantly, the fact that we
can observe dermal DCs but not epidermal LCs migrat-
ing into the cutaneous LN after FITC painting and still
see a normal number of Langerin+ cells in LN and spleenargues that not all Langerin+ cells are derived from epi-
dermal LCs (Figure 5E). Although we are not sure why
expression of DTA under the control of human Langerin
leads to the depletion of epidermal LCs but not other
muLangerin+ cells, it is clear that Langerin-DTA mice
have a selective ablation of only epidermal LCs and
show a clear enhancement of CHS with multiple haptens
and even in cell-transfer experiments.
The enhancement of CHS that we observed in the ab-
sence of LCs indicates that LCs regulate the cutaneous
immune response. Our adoptive transfer experiments
showed that LCs exert their regulatory activity at the
priming rather than effector phase. It is interesting to
Enhanced CHS in LC-Deficient Mice
617Figure 6. Langerin-DTA Mice Have Enhanced
CHS but Not Irritant Contact Dermatitis
(A) Groups of 5–8 Langerin-DTA (Tg+, black
bars) and littermate controls (Tg2, white bars)
were sensitized with 0.5% DNFB or vehicle
alone on shaved abdomens on day 0. All mice
were then challenged with 0.2% DNFB on
their ears on day 5. Data represents the
change of ear thickness over baseline after
24 hr (*p < 0.05).
(B) As in (A) except that mice were sensitized
with 3.0% oxazalone and challenged with
1.0% oxazalone. (**p < 0.001).
(C) Groups of 6–7 Langerin-DTA (Tg+, solid
line) and littermate controls (Tg2, broken line)
were sensitized with 0.5% DNFB (thick lines)
or vehicle alone (thin lines). All mice were
challenged with 0.2% DNFB 5 days later and
monitored daily for change in ear thickness.
(D) Groups of 5–6 Langerin-DTA (black bars)
and littermate controls (white bars) were
challenged on the ear with 0, 0.5%, or 2.5%
SDS. Data represent the change of ear thick-
ness over baseline after 24 hr.
(E) Langerin-DTA (Tg+, solid line) and litter-
mate controls (Tg2, broken line) were chal-
lenged with 5% Benzalkonium chloride (thick
lines, n = 8) or vehicle (thin lines, n = 4) and
monitored for ear swelling after 6, 24, 48,
and 96 hr.
A single representative experiment from at
least three independent experiments is shown.
Error bars are6 standard error.speculate on how LCs might regulate priming. CHS to
DNFB and oxazalone is a CD8- and CD4-mediated
Th1/Tc1 response (Gocinski and Tigelaar, 1990; Wang
et al., 2000). LCs could affect T cell priming through
skewing T cell polarity to a more Th-2 like response.
Alternatively, LCs may favor the development or activa-
tion of regulatory T cells (Probst et al., 2005; Shevach,
2002). There are precedents for DC subsets with such
functions; for example, there are specialized DC pop-
ulations in the lung and gut that secrete IL-10 and pref-
erentially lead to the production of Tregs (Akbari et al.,
2001; McGuirk et al., 2002; Mowat, 2003; Rimoldi et al.,
2005).As with any knockout mouse, we cannot rule out that
the enhanced CHS we observed was due to the absence
of LCs during the development of the skin immune sys-
tem per se. Although such a function would be quite in-
teresting and novel, a number of lines of evidence argue
against it. First, we saw no defects or alterations in
other cell populations in the skin or LN that might have
compensated for the loss of LCs. In addition, immune
responses to Ag injected below the epidermis and to
nonspecific, irritant stimuli were not exaggerated. More-
over, T cells that were primed in a wild-type environment
and transferred into a LC-deficient host did not dem-
onstrate an enhanced response in the LC-deficientFigure 7. Enhanced CHS Can Be Adoptively
Transferred to Wild-Type Mice
(A) Donor Langerin-DTA and littermate con-
trol animals were sensitized with 3.0% oxaz-
alone on day 0. On day 5, 5 3 107 skin-drain-
ing lymph node cells from each strain were
harvested and injected i.v. into groups of 6–8
unmanipulated wild-type FVB mice. Recipi-
ents were ear challenged 2 hr later and the
magnitude of ear swelling was measured af-
ter 24 hr (*p < 0.05).
(B) In the reciprocal experiment, wild-type
FVB mice were sensitized with 3.0% oxazalone and their lymph node cells were adoptively transferred on day 5 into unmanipulated Lan-
gerin-DTA (Tg+, black bars) and littermate controls (Tg2, white bars). There was no significant difference between Langerin-DTA and control
mice that received lymph node cells from sensitized wild-type mice. Recipients of lymph node cells did show significant increase in ear thickness
compared with PBS controls (p < 0.05). These data are representative of three independent experiments.
Error bars are 6 standard error.
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618environment. Thus, it is very likely that the observed en-
hanced CHS response is due to a dynamic lack of regu-
lation from LCs during the priming response and not
from a developmental defect.
Our finding that LCs have regulatory properties in CHS
has obvious implications for their role in other cutane-
ous immune processes such as cutaneous HSV infec-
tion, lupus, GVHD, and tumor immunosurveillance.
By using the Langerin-DTA LC-deficient animals, the
in vivo participation of LCs in these and other disease
models can now be directly examined by us and others.
Experimental Procedures
BACs and Production of Transgenic Mice
Human BAC clone RP11-504o1 was obtained from Invitrogen
(Carlsbad, CA). An IRES sequence (Clontech, Mountainview, CA) fol-
lowed by an attenuated diphtheria toxin gene (tox176, kind gift of
Dr. Ian Maxwell [Maxwell et al., 1986]) was inserted 83 bp 30 of the
stop codon in the 30UTR of exon VI of Langerin by homologous re-
combination in E. coli as previously described (Misulovin et al.,
2001; Yang et al., 1997). The shuttle vector for insertion of IRES-
DTA into Langerin was created by PCR. First, the IRES-DTA con-
struct was generated by overlapping PCR to contain an IRES and
Kozak consensus sequences (from pIRES2EGFP) followed by
tox176 attenuated DTA. Next, the shuttle vector was constructed
by overlapping PCR to include 1021 bp 50 of the insertion site in Lan-
gerin, the IRES-DTA construct, and 1066 bp 30 of the insertion site.
The construct was fully sequenced to eliminate the possibility of
PCR-induced errors. Recombined BAC clones were confirmed by
PCR with oligos flanking the insertion site and by Hyp99I (New Eng-
land Biolabs, Beverly, MA) restriction digest. BAC DNA for microin-
jection was obtained with a Plasmid Maxi Kit (Qiagen, Valencia, CA)
followed by NotI digestion (New England Biolabs), purification by
pulse field agarose gel electrophoresis (Chef II, Biorad, Hercules,
CA), and b-agarase digestion (New England Biolabs). DNA was con-
centrated and transferred into microinjection buffer (10 mM Tris [pH
7.4], 0.1 mM EDTA, 100 mM NaCl) by a 30 kDa molecular weight cut-
off spin column (Millipore, Bedford, MA). DNA concentration was de-
termined by Picogreen assay (Invitrogen) and injected at 1–2 ng/ml
by the Yale Genomics Services Transgenic Mouse Service into pro-
nuclei of (C57BL/6j 3 SJL/j) F2 embryos for huLangerin mice and
into FVB embryos for Langerin-DTA mice. huLangerin mice were
backcrossed with BALB/c, and the Langerin-DTA transgene was
maintained on a pure FVB background. Founders were identified
by PCR via STS SHGC-3151 and SHGC-143488 (see below) located
on the centromeric and telomeric ends of the NotI fragment, respec-
tively.
Oligonucleotides
STS Used to Screen for Transgene-Positive Mice
SHGC-143488: F, 5-gaggcaaatgattggcattctac-3; R, 5-ctgggaaaat
tcaagaagagcct-3; SHCG-3151:F, 5-gtactaatagccagtcattgttcac-3; R,
5-ataaagagtaagatgaatggtcacag-3.
Generation of IRES-DTA
50 IRES: 5-caagtaaagcggccgggatccgcccctctcc-3; 30IRES: 5-catcag
gatcccatggttgtggccatattatc-3; 50 DTA: 5-gccacaaccatggatcctgatga
tgttgttg-3; 30 DTA: 5-cgtgtcaggcgatctttgtgagcggccgctaaactat-3.
Generation of Shuttle Vector
50 A Box: 5-acgcgtcgacgcaggaagaagcttgagagg-3; 30 A Box: 5-ggcg
gaacccggcctggagtctggggaagaaag-3; 50 Insert: 5-ccagactccaggccg
ggttccgcccctctcc-3; 30 Insert: 5-cgtgcaaagtcattcacaaagatcgcctgac
acg-3; 50 B Box: 5-gcgatctttgtgaatgactttgcacgttaatttttc-3; 30 B Box:
5-acgcgtcgactctgtgaagagtggggaacc-3.
Mice
FVB mice were purchased from National Cancer Institute (NCI) Lab-
oratories (Frederick, MD), Harlan (Indianapolis, IN), and Taconic
(Germantown, NY). BALB/c mice were purchased from NCI. All
experiments were performed with 6- to 10-week-old age- and sex-
matched mice. Mice were housed in microisolator cages and fed au-toclaved food and acidified water. The Yale institutional animal care
and use committee approved all mouse protocols.
Antibodies
The following antibodies were used: huLangerin (DCGM4, Beckman
Coulter, Fullerton, CA), muLangerin (929F3 [Valladeau et al., 2002]),
CD11c (N418-FITC and APC, eBioscience, San Diego, CA), I-A/E
(M5/144.15.2-FITC and biotin, Biolegend, San Diego, CA), Vg5
(F536, Pharmingen), CD11b (M1/70-PE, Pharmingen), CD8a (Ly-2-
PE, Pharmingen), mouse anti-Rat Alexa 647 (Invitrogen), and
strep-avadin PE (Invitrogen). NLDC-145 (anti-DEC-205), RA3-6b2
(anti-B220), and 24G2 (anti-FcRg) were purified from hybridoma
supernatants as described (Shlomchik et al., 1993). Conjugation to
biotin or Alexa-647 was performed according to manufacturer’s di-
rections (Invitrogen). huLangerin antibodies were labeled by a Zenon
Bio-XX labeling kit (Invitrogen).
Flow Cytometry
Single-cell suspensions of epidermal cells were obtained from trunk
or ear skin and incubated for 2 hr at 37ºC in 0.3% trypsin (Sigma-
Aldridge, St. Louis, MO) in 150 mM NaCl, 0.5 mM KCl, 0.5 mM glu-
cose. The epidermis was physically separated from the dermis
and disrupted by vortexing. Dermal cells were obtained from sam-
ples from which the epidermis had been removed or from untreated
whole flank skin. Samples were minced and incubated for 2 hr
at 37ºC in collagenase XI (4830 U/ml, Sigma), hyaluronidase
(260 U/ml, Sigma), DNase (0.1 mg/ml, ICN), 10 mM HEPES (Sigma)
in RPMI (Invitrogen). The resulting cells were filtered though a
40 mM filter. Lymph node (axillary, brachial, and inguinal) and spleen
cells were incubated in 400 and 150 U/ml Collagenase D (Roche
Applied Science, Indianapolis, IN), respectively, for 90 min prior to
erythroid cell lysis in ACK buffer (Biowhittaker, Walkersville, MD).
Single-cell suspensions were pretreated for 10 min at 4ºC with
24G2 except when anti-Rat secondaries were used, in which case
cells were blocked with mouse Ig (Sigma). Cells were stained for ex-
tracellular markers as described (Shlomchik et al., 1993). Propidium
iodide (Invitrogen) was used for live-dead discrimination. For intra-
cellular markers, cells were incubated in ethidium monoazide
(EMA, Invitrogen) for live-dead discrimination followed by cytofix/
cytoperm (Pharmingen) as per manufacturer’s directions. Mice
painted with FITC were shaved on their abdomens and 100 ml of
0.5% FITC (Fluorescein isothiocyanate isomer I, Sigma) in acetone:
dibutylphthalate (1:1) was applied 4 days before harvest of the ingui-
nal, axillary, and brachial lymph nodes.
Immunohistochemistry and Immunofluoresence
For immunohistochemistry, transverse tissue sections were ob-
tained and processed as described (Hannum et al., 2000). Sections
were stained with biotinylated anti-MHC-II followed by Streptavidin
alkaline-phosphatase (Invitrogen) as described (Hannum et al.,
2000). For immunofluorescence, epidermal sheets were prepared
by treating mouse ears with Nair (Chursh and Dwight Co, Princeton,
NJ) for 5 min followed by affixing them to slides (epidermis side
down) with double sided adhesive (3M, St. Paul MN). Slides were in-
cubated in 10 mM EDTA in PBS for 2 hr at 37ºC followed by physical
removal of the dermis. Tissue was fixed in acetone at 4ºC for 10 min
and blocked as described (Hannum et al., 2000). Tissues were
stained with MHC-II FITC followed by anti-FITC Alexa 488 (Invi-
trogen) for signal amplification and with biotin-huLangerin followed
by Streptavidin-Alexa 555 (Invitrogen).
Contact Dermatitis
Allergic contact dermatitis was induced in mice as previously de-
scribed (Girardi et al., 2002). In brief, mice were sensitized on day 0
by epicutaneous application of 25 ml of 0.5% DNFB (2,4 dinitrofluro-
benzene, Sigma) in acetone:olive oil (4:1), 100 ml of 3.0% Oxazalone
(4-ethoxymethylene-2-phenyl-2-oxazolin-5-one, Sigma) in ethanol,
or vehicle alone onto dry shaven abdominal skin. On day 5, baseline
ear thickness was measured with an engineer’s micrometer followed
by challenge with 10 ml of 0.2% DNFB or 1.0% oxazalone to both
sides of one ear. Ears were measured 24 hr after challenge and
data are expressed as the ear size at 24 hr minus the baseline thick-
ness. For irritant dermatitis, mice were challenged without prior sen-
sitization with 10 ml to both sides of one ear with the indicated
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619concentration SDS (sodium dodecylsulfate, Sigma) dissolved in wa-
ter. Ear swelling was measured after 24 hr. Mice were also chal-
lenged with 5% Benzalkonium chloride (Sigma) in acetone:olive oil
and ear swelling was measured after 6, 24, 48, and 96 hr.
Adoptive Transfer
For adoptive transfer of allergic contact dermatitis, Langerin-DTA
and/or control mice were sensitized with 3.0% oxazalone to their ab-
domen as well as 10 ml to each paw. After 5 days, single-cell suspen-
sions of lymph node cells (axillary, brachial, popliteal, and inguinal)
were obtained by physical disruption and filtered through a 40 mM
screen. Groups of unsensitized Langerin-DTA and/or control mice
were injected intravenously with 53 107 cells. Two hours later, base-
line ear thickness measurements were obtained and the mice were
challenged with 10 ml of 1.0% oxazalone to both sides of one ear.
Ears were measured 24 hr later and the ear thickness above baseline
was calculated. All donor/recipient pairs were age-matched female
mice that had been maintained on a pure FVB background.
Statistics
Statistical comparisons between groups in CHS experiments were
made with a standard Student’s two-tailed t test. The Mann-Whitney
test was used for comparison between groups in Figure 4C.
Supplemental Data
Supplemental Data include two figures and can be found with this
article online at http://www.immunity.com/cgi/content/full/23/6/
611/DC1/.
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